8-K: Ensysce Biosciences Reports Positive 2024 Financial Results and Strategic Partnership

Ensysce Biosciences announces its fourth quarter and full year 2024 financial results, highlighting a strategic partnership and positive interim results for its PF614-MPAR trial.

Summary

• Ensysce Biosciences reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose.
• A strategic partnership was secured for the manufacture and commercial launch of PF614 and PF614-MPAR.
• Positive interim results were generated from a groundbreaking trial on PF614-MPAR.
• Cash and cash equivalents were $3.5 million as of December 31, 2024, compared to $1.1 million as of December 31, 2023.
• For the year, cash from financing activities of $9.9 million exceeded cash used in operations of $7.5 million.
• Funding under federal grants totaled $1.3 million for the fourth quarter of 2024 and $5.2 million for the full year.
• R&D expenses were $3.8 million for the fourth quarter of 2024 and $7.2 million for the full year.
• G&A expenses were $1.1 million in the fourth quarter of 2024 and $4.7 million for the full year.
• Net loss attributable to common stockholders for the fourth quarter of 2024 was $3.6 million, and for the full year, it was $8.0 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strategic partnership, positive clinical trial results, and improved cash position. However, the ongoing net losses and inherent risks of clinical-stage drug development temper the overall outlook.

Positives

• The strategic partnership for PF614 and PF614-MPAR commercialization is a significant step forward.
• Positive interim results from the PF614-MPAR-102 study indicate the potential for overdose protection.
• FDA feedback on the PF614 phase 3 study design allows the company to move forward with clinical trials.
• Increased cash and cash equivalents provide financial stability.
• Substantial federal grant funding supports the MPAR clinical program.

Negatives

• The company reported a net loss of $8.0 million for the full year 2024.
• The company expects to continue to incur losses for the foreseeable future as a clinical stage biotech company.

Risks

• The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy.
• Ensysce may encounter problems or delays in clinical development.
• There is no guarantee that any product candidate will ever receive regulatory approval or be successfully commercialized.
• The company's business is subject to risks and uncertainties, including possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements.

Future Outlook

Ensysce anticipates losses for the foreseeable future as it continues research and development efforts. The company plans to disrupt the analgesic market with novel protection against overdose and abuse, aiming for regulatory approval and commercialization of its product candidates.

Management Comments

• Dr. Lynn Kirkpatrick, CEO, stated that the team continued to make significant strides in the fourth quarter to deliver what they believe are the Next Generation opioid analgesics with both abuse and overdose protection.
• Dr. Kirkpatrick is pleased that Ensysce concluded 2024 and entered 2025 in a very favorable position.
• Dr. Kirkpatrick noted the FDA's recent focus on commercialization of new drug products that address and treat pain.

Industry Context

Ensysce is positioning itself to address the opioid crisis by developing abuse-deterrent and overdose-protected pain medications. This aligns with the FDA's focus on new drug products that address and treat pain while mitigating the risks of abuse and overdose.

Comparison to Industry Standards

• Ensysce's TAAP and MPAR technologies aim to provide safer opioid alternatives, addressing a critical need in the pain management market.
• Companies like Collegium Pharmaceutical and Teva Pharmaceutical also focus on abuse-deterrent opioid formulations, but Ensysce's approach with trypsin activation and overdose protection offers a unique mechanism.
• The $14 million NIDA grant highlights the significance of Ensysce's MPAR program in addressing the opioid crisis, reflecting a level of government support comparable to other leading research initiatives in the field.

Stakeholder Impact

• Shareholders may be encouraged by the strategic partnership and positive clinical trial results.
• Patients suffering from severe pain could benefit from safer and more effective opioid alternatives.
• The company's efforts to reduce opioid abuse and overdose could have a positive impact on public health.

Next Steps

• Prepare for the expected start of enrollment of the PF614 phase 3 clinical study in the second quarter of 2025.
• Finalize the selection of clinical sites and an experienced team to execute the PF614 phase 3 trial.
• Continue to enroll subjects for parts 2 and 3 of the PF614-MPAR-102 study over the next year.
• Continue non-clinical studies to support moving the OUD drug candidate PF9001 into IND enabling work in the coming year.

Key Dates